# The collected information (brief, optional): [1] Foundational pharmacotherapy has transformed outcomes in
![# The collected information (brief, optional): [1] Foundational pharmacotherapy has transformed outcomes in](https://aiinfluence.pubdat.com/wp-content/uploads/2025/09/image_01_1759223091.png)
The collected information (brief, optional): [1] Foundational pharmacotherapy has transformed outcomes in
Foundational pharmacotherapy has significantly improved outcomes for heart failure with reduced left ventricular ejection fraction (HFrEF), setting the stage for new therapeutic avenues like vericiguat, a soluble guanylate cyclase stimulator [1]. Recent trials, such as VICTORIA, have further delineated vericiguat’s role in managing HFrEF, particularly by reducing the composite endpoint of cardiovascular death or first hospitalisation for heart failure in patients with recent worsening of their condition [1].
Summary of the Trend
Foundational pharmacotherapy has significantly improved outcomes for patients with heart failure with reduced left ventricular ejection fraction (HFrEF) [1]. In this evolving landscape, vericiguat, identified as a soluble guanylate cyclase stimulator, is being positioned within the management of this condition, with its role being delineated by recent large clinical trials [1].
Specifically, the VICTORIA trial enrolled patients with recently worsened heart failure, defined as a hospitalization within the previous six months or outpatient intravenous diuretic use within three months [1]. This study demonstrated that vericiguat effectively reduced the primary composite endpoint of cardiovascular death or first hospitalization for heart failure [1]. The observed reduction in this composite endpoint was primarily driven by a decrease in hospitalizations, with no clear effect on cardiovascular death [1].
Critical Analysis
While vericiguat demonstrates a notable ability to reduce the composite endpoint of cardiovascular death or first hospitalization for heart failure in patients with recent worsening heart failure, a critical examination reveals a significant limitation in its overall impact [1]. Specifically, the VICTORIA trial indicated that this reduction was “largely via fewer hospitalisations, without a clear effect on cardiovascular death” [1]. This finding prompts a closer look at the drug’s true benefit, suggesting that its primary role might be in managing morbidity rather than directly influencing mortality, which is a key objective in advanced heart failure treatment.
The absence of a clear effect on cardiovascular death distinguishes vericiguat from other foundational pharmacotherapies in heart failure that have demonstrated survival benefits [1]. This counterpoint raises important questions about its positioning within the therapeutic algorithm, particularly for clinicians and patients who prioritize prolonging life alongside improving quality of life and reducing hospital burden. While fewer hospitalizations are undeniably beneficial for patient well-being and healthcare resource utilization, the lack of a mortality signal suggests that vericiguat may not address the underlying progressive nature of HFrEF to the same extent as agents that have shown a clear impact on survival.
Furthermore, the trial’s focus on patients with recent worsening heart failure, defined by hospitalization or outpatient intravenous diuretic use, indicates a population with advanced disease [1]. For such a vulnerable group, the primary benefit observed—reduction in hospitalizations—is valuable, yet the absence of a discernible effect on cardiovascular death may temper expectations regarding its capacity to fundamentally alter long-term prognoses. This specificity also limits the generalizability of its mortality impact to broader HFrEF populations who may not have experienced recent decompensation. The drug’s role thus appears to be more focused on managing acute exacerbations and their sequelae rather than offering a comprehensive solution for survival improvement.
This analysis underscores that while vericiguat represents a valuable addition for managing specific aspects of HFrEF, particularly in reducing the burden of hospitalizations, its limitations regarding cardiovascular mortality warrant careful consideration when integrating it into treatment strategies [1]. Its efficacy profile suggests a targeted benefit, reinforcing the need for a multi-faceted approach to heart failure management that combines various therapies to address both morbidity and mortality outcomes.
Implication for Practice or Policy
Given the evidence from trials demonstrating that vericiguat can reduce the primary composite endpoint of cardiovascular death or first hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF) who have experienced recent worsening heart failure [1], clinical guidelines and treatment protocols should consider incorporating vericiguat as a targeted intervention for this specific high-risk population. Specifically, for patients recently hospitalized for heart failure or requiring outpatient intravenous diuretics, integrating vericiguat could serve to reduce the incidence of future hospitalizations, thereby potentially improving patient outcomes and reducing healthcare resource utilization [1].
Closing Reflection
The continued integration of therapies like vericiguat into HFrEF management represents a crucial advancement, especially for patients with recent worsening heart failure [1]. Future efforts must focus on optimizing patient selection and refining long-term treatment strategies to further improve cardiovascular outcomes.
Signature
Dr Omar Tujjar – MD, MA, MPH, PGDip, EDAIC, EDRA Consultant in Anaesthesia, Intensive Care, and Pain Medicine National Orthopaedic Hospital Cappagh Dublin, Ireland (++353) 085 1781872
